Edgardo Santos, MD, FACP, FASCO
@EddieSantosMD
Followers
48
Following
37
Statuses
31
Medical Director-Broward, Florida; The Oncology Institute of Hope & Innovation; Thoracic Oncology; Clinical Associate Professor, Florida Atlantic University
Fort Lauderdale, Florida
Joined January 2025
RT @lungoncdoc: Burnout in oncology is a real concern, especially for early-career oncologists. Addressing it is essential for patient car…
0
5
0
RT @DrJNaidoo: Ph Ib Trial Ivonescimab (PD-1/VEGF bispecific)+Plt/Etop in 1L ES SCLC @JTOonline: - Ivo (3 dose levels)+plt/etopx4 ➡️ivo mai…
0
26
0
RT @Tony_Calles: Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Resul…
0
15
0
RT @FCCPulmon: 🎗️Hoy es el Día Mundial contra el Cáncer. Un día para recordar que la prevención, la investigación y el apoyo a quienes pasa…
0
1
0
0
1
0
RT @edgardo_ny: Join us at La Isla del Encanto for this great and unique CME/CE event. Visit for more information.…
0
2
0
RT @PrelajArsela: Great time with friends such as @StephenVLiu @MartinReck2 and amazing conference organized from @delvysra discussions a…
0
2
0
RT @FordePatrick: Dr. @BenCreelan who has pioneered cell therapy for NSCLC, gives a great talk on TIL/cell therapy, always seems to be on h…
0
11
0
RT @dplanchard: A very pleasant moment of scientific exchange on lung cancer and conviviality with @HosseinBorghaei @GustaveRoussy A big th…
0
4
0
0
2
0
RT @LuisRaezMD: Thanks to @delvysra and @FCCPulmon for this amazing course and make us feel at home. #ITCD2025 #lungcancer #lcsm
@AMorales…
0
14
0
0
2
0
RT @HHorinouchi: 🔥European Journal of Cancer🆙 ✅Efficacy and Safety of Immune Checkpoint Inhibition Combined with Concurrent Chemoradiothera…
0
16
0
RT @FordePatrick: Dr. @peters_solange with an outstanding overview of novel IO-IO combinations in advanced NSCLC #ITCD2025
0
7
0
RT @StephenVLiu: Dr. @peters_solange at #ITCD2025 gives a masterful talk on the next generation of checkpoint inhibitors and how novel agen…
0
20
0
Fascinating topics on immunotherapy approaches. Going deeper on checkpoint inhibitors, then BiTES, Bispecifics, TIL, CAR-T, and finally, vaccines in lung cancer at the International Thoracic Cancer Debates. @FCCPulmon @BenCreelan @peters_solange @EnriquetaFelip @FLASCO_ORG
0
0
0
RT @FCCPulmon: Dr. Ignacio Gil Bazo from the Vithas Vitoria Oncology Institute brings an interesting question: “What to do after first-line…
0
1
0
RT @lungoncdoc: @dgermain21 Lung cancer diagnoses in pts with no smoking history are on the rise, now accounting for >20% of new cases in t…
0
1
0